Blockbuster Patents Expiring in Succession... Can Celltrion Sustain Its Growth?
Targeting a Market Worth Approximately KRW 408 Trillion with a Portfolio of 41 by 2038
Mirae Asset Securities Raises Target Price from KRW 280,000 to KRW 350,000
"Biosimilar Patent Expirations Expected to Drive Growth"
With blockbuster biopharmaceutical patents continuing to expire and countries introducing policies to promote biosimilars, the global biosimilar market is expected to grow even faster. Securities analysts cite Celltrion as a major beneficiary, thanks to its in-house business capabilities spanning biosimilar development, regulatory approval, production and global sales. Celltrion plans to expand its biosimilar portfolio to 41 products by 2038 and target a market worth approximately KRW 408 trillion.
According to the pharmaceutical and biotech industries on November 20, Mirae Asset Securities recently maintained its “Buy” rating on Celltrion and raised its target price by 25%, from KRW 280,000 to KRW 350,000. Seungmin Kim, an analyst at Mirae Asset Securities, described Celltrion as “a global Tier 1 biosimilar company with a portfolio of approved products, next-generation pipelines, in-house production of drug substances, and direct sales networks in the United States and Europe.” He also forecast that the company’s competitiveness would improve as the prescribing environment for biosimilars improves and development costs and timelines are reduced.
Kim raised his fourth-quarter earnings forecasts for Celltrion this year to KRW 1.7078 trillion in revenue and KRW 601 billion in operating profit. For full-year 2026, he forecast revenue of KRW 5.8216 trillion and operating profit of KRW 1.8999 trillion. He cited the U.S. launch of Omlyclo, a U.S. exclusive supply agreement for Aptozma, and the listing of Stoboclo and Osenvelt as preferred drugs by pharmacy benefit managers (PBMs). He expects high-margin new products to account for more than 70% of biopharmaceutical sales. His forecasts for 2027 are KRW 6.938 trillion in revenue and KRW 2.512 trillion in operating profit.
Celltrion's foreign ownership rose by 4.62 percentage points, from 21.06% on January 2 this year to 25.68% on November 16. The company said expectations for earnings growth amid the expansion of the biosimilar market had been reflected in investor sentiment.
Celltrion plans to increase its number of biosimilars on the market from the current 11 to 41 by 2038. This would expand the global market it can target more than fourfold, from approximately KRW 85 trillion this year to approximately KRW 408 trillion in 2038.
In oncology, Celltrion is developing biosimilars CT-P6 SC (a subcutaneous formulation of Herceptin), CT-P51 (Keytruda) and CT-P44 (Darzalex). The combined global market for the three originator products in 2025 is estimated at approximately $52.1 billion (approximately KRW 72.94 trillion). In the autoimmune disease field, the five biosimilars under development are CT-P53 (Ocrevus), CT-P55 (Cosentyx), CT-P52 (Taltz), CT-P45 (Entyvio) and CT-P68 (Tremfya). The combined global market for these originator products in 2025 is approximately $45 billion (approximately KRW 63 trillion).
As global regulatory authorities have successively eased requirements for biosimilar development, Celltrion is reducing the number of participants in its clinical trials accordingly. The number of patients in its global Phase 3 trials has been reduced from 375 to 153 for CT-P55, from 606 to 220 for CT-P51, and from 486 to 394 for CT-P44. The company is applying the same approach to 22 undisclosed biosimilars in development. It plans to launch follow-on products in succession to coincide with the expiration of patents on the corresponding originator drugs. The development costs saved will be reinvested in follow-on biosimilars and new drug development.
In its novel drug business, Celltrion is developing 25 candidates, including antibody-drug conjugates (ADCs), bispecific antibodies and obesity treatments, through a combination of in-house development and open innovation. The company aims to increase the number of candidates in clinical development from the current four to eight in 2027 and at least 15 in 2028. Three ADCs in clinical development (CT-70, CT-71 and CT-73) have received Fast Track designation from the U.S. Food and Drug Administration (FDA). The obesity treatment candidate CT-G32, which targets four hormonal pathways, recently had its preclinical results released, and the company is pursuing submission of an investigational new drug (IND) application in 2027. It aims to submit an IND application for an oral obesity treatment in 2028.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Celltrion official said, “We are seeing growing investor interest as sales of new products increase and development of our follow-on portfolio gathers momentum.” The official added, “As our novel drug pipeline delivers results, our corporate value as a drug development company will rise further.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.